388
Participants
Start Date
August 3, 2022
Primary Completion Date
August 9, 2023
Study Completion Date
September 18, 2023
Semaglutide J
Participants will initially receive 0.25 mg subcutaneous injections of semaglutide J OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
Semaglutide B
Participants will initially receive 0.25 mg subcutaneous injections of semaglutide B OW and the dose will be then escalated once in 4 weeks for 8 weeks until the target maintenance dose of 1.0 mg is reached which will be maintained for a period of 20 weeks: 0.25 mg (week 1 to week 4), 0.5 mg (week 5 to week 8), 1.0 mg (week 9 to week 28).
Shop#1 Health Emporium, Midrand
Dr A Amod, Durban
Precise Clinical Solutions (Pty) Ltd, Durban
Dr Pillay's Rooms, Durban
Medi-Clinic Bloemfontein, Bloemfontein
Moriana Clinical Research, Winnie Mandela
N.Y. Family Practice Physicians, Woodhaven
Tristar Clin Investigations, PC, Philadelphia
PharmQuest Life Sciences LLC, Greensboro
Whiteville Medical Assoc, PA, Whiteville
Spartanburg Medical Research, Spartanburg
Encore Medical Research LLC, Hollywood
South Broward Research LLC, Miramar
South Broward Research LLC, Pembroke Pines
New Horizon Research Center, Miami
International Research Associates, LLC_Miami, Miami
Innovative Research of W Florida Inc., Clearwater
Innovative Research of W FL, Clearwater
The Research Group of Lexington LLC, Lexington
Advanced Med Res Maumee, Maumee
Arcturus Healthcare, PLC., Troy
Elite Research Center, Flint
Velocity Clinical Res-Dallas, Dallas
Tapia Internal Medicine Clinic, Paris
Martin Diagnostic Clinic, Tomball
Sugar Lakes Family Practice PA, Sugar Land
Elligo Clin Res Centre, Austin
Elite Clinical Trials, Blackfoot
Velocity Clin Res Los Angeles, Los Angeles
Med Partners, Inc., Toluca Lake
Velocity Clinical Research San Diego, La Mesa
San Diego Family Care_San Diego, San Diego
University Clin Investigators, Tustin
LCGK Research, San Carlos
Diabetologicka ambulancia MUDr. Iveta Markova s.r.o, Nitra
MUDr. Jan Culak, s.r.o., Prievidza
Diabetologicka ambulancia DIASTYLE s.r.o., Banská Bystrica
BTC of New Bedford, LLC, New Bedford
Ocean West Research Clinic, Surrey
G.A. Research Associates Ltd., Moncton
Nova Scotia Hlth Halifax, Halifax
Centricity Research Brampton, Brampton
Centricity Research Etobicoke, Etobicoke
Wharton Med Clin Trials, Hamilton
Milestone Research, London
Recherche GCP Research, Montreal
LMC Clin Rsrch Inc. (Montreal), Montreal
Manna Research Inc., Pointe-Claire
"Beata Mikłaszewicz&Dariusz Dąbrowski CARDIAMED s.j.", Legnica
ETG Lublin, Lublin
ETG Lublin, Lublin
Osteo Medic s.c. Artur Racewicz Jerzy Supronik, Bialystok
M2M Badania Kliniczne, Chorzów
NZOZ Gdanska Poradnia Cukrzycowa Sp.z o.o., Gdansk
Krakowskie Centrum Medyczne Sp. z o.o., Krakow
FutureMeds Sp. z o.o. Lodz, Lodz
"Centrum Medyczne Diabetika", Radom
PANSTWOWY INSTYTUT MEDYCZNY MSWiA, Warsaw
Diabetologicka ambulancia DIAMO s.r.o., Kežmarok
IVAMEDIC s.r.o., Košice
DIA - SANTMART, s.r.o., Ambulancia diabetologie a poruch latkovej premeny a vyzivy, Martin
MEDI-DIA s.r.o., Sabinov
Prinshof Medical Campus, Pretoria
Jongaie Research, Pretoria
Clinical Trial Systems (CTC), Pretoria
Lead Sponsor
Novo Nordisk A/S
INDUSTRY